128 related articles for article (PubMed ID: 2681555)
1. Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group.
Rustin GJ; Gennings JN; Nelstrop AE; Covarrubias H; Lambert HE; Bagshawe KD
J Clin Oncol; 1989 Nov; 7(11):1667-71. PubMed ID: 2681555
[TBL] [Abstract][Full Text] [Related]
2. Serum CA 125 level allows early identification of nonresponders during induction chemotherapy.
Makar AP; Kristensen GB; Børmer OP; Tropé CG
Gynecol Oncol; 1993 Apr; 49(1):73-9. PubMed ID: 8482563
[TBL] [Abstract][Full Text] [Related]
3. [A monoclonal antibody RIA as an antigenic determinant (CA 125) in ovarian cancer patients].
Lian LJ
Zhonghua Fu Chan Ke Za Zhi; 1985 Sep; 20(5):257-60, 317. PubMed ID: 2417787
[No Abstract] [Full Text] [Related]
4. Serological monitoring of epithelial ovarian cancer.
Fisken J; Leonard RC; Badley A; Jönrup I; Aspinall L; Sturgeon C; Roulston JE
Dis Markers; 1991; 9(3-4):175-90. PubMed ID: 1813209
[TBL] [Abstract][Full Text] [Related]
5. Savings obtained by CA-125 measurements during therapy for ovarian carcinoma. The North Thames Ovary Group.
Rustin GJ; Nelstrop A; Stilwell J; Lambert HE
Eur J Cancer; 1992; 28(1):79-82. PubMed ID: 1567697
[TBL] [Abstract][Full Text] [Related]
6. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer.
Einhorn N; Bast RC; Knapp RC; Tjernberg B; Zurawski VR
Obstet Gynecol; 1986 Mar; 67(3):414-6. PubMed ID: 2418395
[TBL] [Abstract][Full Text] [Related]
7. [New prospects in the combined use of tumor markers in epithelial neoplasms of the ovary].
Indraccolo SR; Cecchi A; Thodos A; Brandi S; Carta G
Ann Ostet Ginecol Med Perinat; 1991; 112(1):36-40. PubMed ID: 1929097
[TBL] [Abstract][Full Text] [Related]
8. [Experiences with CA 125, a tumor marker for malignant epithelial ovarian tumors].
Crombach G; Zippel HH; Würz H
Geburtshilfe Frauenheilkd; 1985 Apr; 45(4):205-12. PubMed ID: 2408962
[TBL] [Abstract][Full Text] [Related]
9. CA 125 for the monitoring of ovarian carcinoma during primary therapy.
Lavin PT; Knapp RC; Malkasian G; Whitney CW; Berek JC; Bast RC
Obstet Gynecol; 1987 Feb; 69(2):223-7. PubMed ID: 2433652
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
11. Initial assessment of tumor-associated antigen CA-125 in patients with ovarian, cervical, and testicular tumors.
Buamah PK; Cornell C; Skillen AW; Cantwell BM; Harris AL
Clin Chem; 1987 Jul; 33(7):1124-5. PubMed ID: 3036401
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction.
Hunter VJ; Daly L; Helms M; Soper JT; Berchuck A; Clarke-Pearson DL; Bast RC
Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1164-7. PubMed ID: 2171337
[TBL] [Abstract][Full Text] [Related]
13. Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy.
van der Burg ME; Lammes FB; van Putten WL; Stoter G
Gynecol Oncol; 1988 Jul; 30(3):307-12. PubMed ID: 3164697
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic value of CA 125 initial half-life measured during first-line chemotherapy in 62 patients with epithelial ovarian cancer stage III or IV].
Riedinger JM; Barillot I; Coudert B; Fargeot P; Berriolo-Riedinger A; Guerrin J
Bull Cancer; 1996 Aug; 83(8):654-63. PubMed ID: 8869046
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of post chemotherapy serum CA 125 in epithelial ovarian cancer.
Teeling M; McGing P; Carney DN
Ir J Med Sci; 1989 Mar; 158(3):59-62. PubMed ID: 2745033
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunoassay of the CA 12 5 antigen in ovarian carcinomas: advantages compared with CA 19-9 and CEA.
Ricolleau G; Chatal JF; Fumoleau P; Kremer M; Douillard JY; Curtet C
Tumour Biol; 1984; 5(3-4):151-9. PubMed ID: 6594738
[TBL] [Abstract][Full Text] [Related]
17. [Tumor-associated antigens and fibrin derivatives as reaction products of ovarian cancer].
Schröck R; Hafter R; Schmid L; Babic R; Ulm K; Gössner W; Graeff H
Geburtshilfe Frauenheilkd; 1986 Jan; 46(1):1-10. PubMed ID: 2420679
[TBL] [Abstract][Full Text] [Related]
18. [A CA 12-5 prognostic score for epithelial ovarian cancers].
Klein M; Rosen A; Sevelda P; Spona J; Beck A
Gynakol Rundsch; 1990; 30 Suppl 1():70-2. PubMed ID: 2079305
[No Abstract] [Full Text] [Related]
19. Tumor-associated antigen Ca 125 before and during the treatment of ovarian carcinoma.
Kivinen S; Kuoppala T; Leppilampi M; Vuori J; Kauppila A
Obstet Gynecol; 1986 Apr; 67(4):468-72. PubMed ID: 3008051
[TBL] [Abstract][Full Text] [Related]
20. Use of CA-125 response to predict survival parameters of patients with advanced ovarian carcinoma.
Ron IG; Inbar M; Gelernter I; Lewysohn O; Ayalon D; Dale J; Chaitchik S
Acta Obstet Gynecol Scand; 1994 Sep; 73(8):658-62. PubMed ID: 7941993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
